Emergency Contraception

References

• Demers L. The morning-after pill. N Engl J Med 1971;284:1034–6
   PubMed Web of Science ®Google Scholar
• FDA considers DES safe as ‘morning-after pill’. JAMA 1973;224:1581–8
   Google Scholar
• Johnson JH. Contraception – the morning after. Fam Plann Perspect 1984;16:266
   Google Scholar
• Yuzpe A, Thurlow H, Ramzy I, et al. Postcoital contraception – A pilot study. J Reprod Med 1974;13:53–8
   PubMed Web of Science ®Google Scholar
• Valle G. The problem of postcoital contraception using oral progestins. Aggiorn Ostet Ginecol 1975;8:127–8
   Google Scholar
• Task Force on Postovulatory Methods of Fertility Regulation. Randomised controlled trial of levonorgestrel versus the Yuzpe regimen of combined oral contraception for emergency contraception. Lancet 1998;352:428–33
   Google Scholar
• Guillebaud J. Time for emergency contraception with levonorgestrel alone. Lancet 1998;352:416–7
   Google Scholar
• Gemzell-Danielsson K, Meng CX. Emergency contraception: potential role of ulipristal acetate. Int J Women’s Health 2010;2:53–61
   PubMedGoogle Scholar
• Yuzpe AA, Lancee WJ. Ethinylestradiol and dl-norgestrel as a postcoital contraceptive. Fertil Steril 1977;28:932–6
   PubMed Web of Science ®Google Scholar
• Trussell J, Rodriguez G, Ellertson C. Updated estimates of the effectiveness of the Yuzpe regimen of emergency contraception. Contraception 1999;59:147–51
   PubMed Web of Science ®Google Scholar
• Vasilakis C, Jick SS, Jick H. The risk of venous thromboembolism in users of postcoital contraceptive pills. Contraception 1999;59:79–83
   PubMed Web of Science ®Google Scholar
• Glasier A. Emergency postcoital contraception. N Engl J Med 1997;337:1058–64
   PubMed Web of Science ®Google Scholar
• Cheng L, Che Y, Gülmezoglu AM. Interventions for emergency contraception. Cochrane Database Syst Rev 2012;8:CD001324. doi: 10.1002/14651858.CD001324.pub4
   PubMed Web of Science ®Google Scholar
• Glasier AF, Cameron ST, Fine PM, et al. Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non-inferiority trial and meta-analysis. Lancet 2010;13:555–62
   Google Scholar
• Strayer SM, Couchenour RL. Combined oral contraceptives versus levonorgestrel for emergency contraception. J Fam Pract 1998;47:417
   Google Scholar
• von Hertzen HG, Piaggio G, Van Look PF. Emergency contraception with levonorgestrel or the Yuzpe regimen. Task Force on Postovulatory Methods. Lancet 1998;352:1939
   PubMed Web of Science ®Google Scholar
• von Hertzen H, Piaggio G, Ding J, et al; WHO Research Group on Post-ovulatory Methods of Fertility Regulation. Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomised trial. Lancet 2002;360:1803–10
   PubMed Web of Science ®Google Scholar
• Piaggio G, von Hertzen H, Grimes DA, Van Look PF. Timing of emergency contraception with levonorgestrel or the Yuzpe regimen. Task Force on Postovulatory Methods of Fertility Regulation. Lancet 1999;353:721
   PubMed Web of Science ®Google Scholar
• Ho PC, Kwan MS. A prospective randomized comparison of levonorgestrel with the Yuzpe regimen in post-coital contraception. Hum Reprod 1993;8:389–92
   PubMed Web of Science ®Google Scholar
• Durand M, del Carmen Cravioto M, Raymond EG, et al. On the mechanisms of action of shortterm levonorgestrel administration in emergency contraception. Contraception 2001;64:227–34
   PubMed Web of Science ®Google Scholar
• Marions L, Cekan SZ, Bygdeman M, Gemzell-Danielsson K. Effect of emergency contraception with levonorgestrel or mifepristone on ovarian function. Contraception 2004;69:373–7
   PubMed Web of Science ®Google Scholar
• Marions L, Hultenby K, Lindell I, et al. Emergency contraception with mifepristone and levonorgestrel: mechanism of action. Obstet Gynecol 2002;100:65–71
   PubMed Web of Science ®Google Scholar
• Croxatto HB, Brache V, Pavez M, et al. Pituitary-ovarian function following the standard levonorgestrel emergency contraceptive dose or a single 0.75-mg dose given on the days preceding ovulation. Contraception 2004;70:442–50
   PubMed Web of Science ®Google Scholar
• Lalitkumar PG, Lalitkumar S, Meng CX, et al. Mifepristone, but not levonorgestrel, inhibits human blastocyst attachment to an in vitro endometrial three-dimensional cell culture model. Hum Reprod 2007;22:3031–7
   PubMed Web of Science ®Google Scholar
• Müller AL, Llados CM, Croxatto HB. Postcoital treatment with levonorgestrel does not disrupt postfertilization events in the rat. Contraception 2003;67:415–9
   PubMed Web of Science ®Google Scholar
• Ortiz ME, Ortiz RE, Fuentes MA, et al. Post-coital administration of levonorgestrel does not interfere with post-fertilization events in the new-world monkey Cebus apella. Hum Reprod 2004;19:1352–6
   PubMed Web of Science ®Google Scholar
• Novikova N, Weisberg E, Stanczyk FZ, et al. Effectiveness of levonorgestrel emergency contraception given before or after ovulation – a pilot study. Contraception 2007;75:112–8
   PubMed Web of Science ®Google Scholar
• Ho PC, et al. Mifepristone: contraceptive and non-contraceptive Uses. Current Opinions Obstet Gynecol 2002;14:325–30
   PubMed Web of Science ®Google Scholar
• Wertheimer RA. Emergency postcoital contraception. Am Fam Physician 2000;62:2287–92
   PubMed Web of Science ®Google Scholar
• Shoupe D, Mishell DR Jr, Page MA, et al. Effects of the antiprogesterone RU 486 in normal women. II. Administration in the late follicular phase. Am J Obstet Gynecol 1987;157:1421–6
   PubMed Web of Science ®Google Scholar
• Ledger WL, Sweeting VM, Hillier H, Baird DT. Inhibition of ovulation by low-dose mifepristone (RU 486). Hum Reprod 1992;7:945–50
   PubMed Web of Science ®Google Scholar
• van der Stege JG, Pahl-van Beest EH, Beerthuizen RJ, et al. Effects of a preovulatory single low dose of mifepristone on ovarian function. Eur J Contracept Reprod Health Care 2006;11:104–8
   PubMed Web of Science ®Google Scholar
• Gemzell-Danielsson K, Svalander P, Swahn ML, et al. Effects of a single post-ovulatory dose of RU486 on endometrial maturation in the implantation phase. Hum Reprod 1994;9:2398–404
   PubMed Web of Science ®Google Scholar
• Gemzell-Danielsson K, Swahn ML, Svalander P, Bygdeman M. Early luteal phase treatment with mifepristone (RU 486) for fertility regulation. Hum Reprod 1993;8:870–3
   PubMed Web of Science ®Google Scholar
• Swahn ML, Gemzell K, Bygdeman M. Contraception with mifepristone. Lancet 1991;12:942–3
   Google Scholar
• Stratton P, Levens ED, Hartog B, et al. Endometrial effects of a single early luteal dose of the selective progesterone receptor modulator CDB- 2914. Fertil Steril 2010;93:2035–41
   PubMed Web of Science ®Google Scholar
• Creinin MD, Schlaff W, Archer DF, et al. Progesterone receptor modulator for emergency contraception: a randomized controlled trial. Obstet Gynecol 2006;108:1089–97
   PubMed Web of Science ®Google Scholar
• Fine P, Mathé H, Ginde S, et al. Ulipristal acetate taken 48–120 hours after intercourse for emergency contraception. Obstet Gynecol 2010;115:257–63
   PubMed Web of Science ®Google Scholar
• Trussel J, Rodriquesz G, Ellerston C. New estimates of the effectiveness of the Yuzpe regimen or emergency contraception. Contraception 1998;57:363–9
   PubMed Web of Science ®Google Scholar
• Massai MR, Forcelledo ML, Brache V, et al. Does meloxicam increase the incidence of anovulation induced by single administration of levonorgestrel in emergency contraception? A pilot study. Hum Reprod 2007;22:434–9. Epub 2006 Sep 15
   PubMed Web of Science ®Google Scholar
• Croxatto HB, Brache V, Pavez M, et al. Pituitary-ovarian function following the standard levonorgestrel emergency contraceptive dose or a single 0.75-mg dose given on the days preceding ovulation. Contraception. 2004;70:442–50
   PubMed Web of Science ®Google Scholar
• Brache V, Cochon L, Jesam C, et al. Immediate pre-ovulatory administration of 30 mg ulipristal acetate significantly delays follicular rupture. Hum Reprod. 2010;25(9):2256–63. doi: 10.1093/humrep/deq157. Epub 2010 Jul 15
   PubMedGoogle Scholar
• Cameron S. Emergency contraception with Ulipristal. Lecture at the ESC congress Athens, Greece, 20.-23.6.2012
   Google Scholar
• Rodriguez MI, Godfrey EM, Warden M, Curtis KM. Prevention and management of nausea and vomiting with emergency contraception: a systematic review. Contraception. 2012 Oct 31. pii: S0010-7824(12)00883–9. doi: 10.1016/j.contraception.2012.09.031. [Epub ahead of print]
   Google Scholar
• (a) Belluck, Pam (June 6, 2012). No abortion role seen for morning-after pill. The New York Times: p. A1; (b) Belluck, Pam (June 6, 2012). Drug's nickname may have aided politicization. The New York Times: p. A14
   Google Scholar
• International Federation of Gynecology and Obstetrics (FIGO) and International Consortium for Emergency Contraception (ICEC) (April 4, 2011). Mechanism of action: How do levonorgestrel-only emergency contraceptive pills (LNG ECPs) prevent pregnancy? London: International Federation of Gynecology and Obstetrics
   Google Scholar
• MedicineNet.com > Levonorgestrel - oral; Retrieved on April 3, 2010
   Google Scholar
• Kovalevsky G, Ballagh SA, Stanczyk FZ, et al. Levonorgestrel effects on serum androgens, sex hormone-binding globulin levels, hair shaft diameter, and sexual function. Fertil Steril 2010;93:1997–2003. doi:10.1016/j.fertnstert.2008.12.095. PMID 19394598
   PubMed Web of Science ®Google Scholar
• Mansour D 2013, personal information
   Google Scholar
• Cleland K, Zhu H, Goldstuck N, et al. The efficacy of intrauterine devices for emergency contraception: a systematic review of 35 years of experience. Hum Reprod. 2012;27:1994–2000. doi:10.1093/humrep/des140. Epub 2012 May 8
   PubMed Web of Science ®Google Scholar
• Belden P, Harper CC, Speidel JJ. The copper IUD for emergency contraception, a neglected option. Contraception 2012;85:338–9
   Google Scholar
• Wu S, Godfrey EM, Wojdyla D, et al. Copper T380A intrauterine device for emergency contraception: a prospective, multicentre, cohort clinical trial. BJOG 2010;117:1205–10
   PubMed Web of Science ®Google Scholar
• Zhou L, Xiao B. Emergency contraception with Multiload Cu-375 SL IUD: a multicenter clinical trial. Contraception 2001;64:107–12
   PubMed Web of Science ®Google Scholar
• Turok DK, Gurtcheff SE, Handley E, et al. A pilot study of the Copper T380A IUD and oral levonorgestrel for emergency contraception. Contraception 2010;82:520–5
   Google Scholar
• Wildemeersch D 2013, personal information
   Google Scholar
• D’Souza RE, Masters T, Guillebaud J. Randomised controlled trial assessing the acceptability of GyneFix® versus Gyne-T380S® for emergency contraception. J Family Planning and Reproductive Health Care 2003;29:23–29
   Google Scholar
• World Health Organization. Media centre. Emergency contraception. Fact sheet No 244, July 2012
   Google Scholar
• Salcedo J, Rodriguez MI, Curtis KM, Kapp N. When can a woman resume or initiate contraception after taking emergency contraceptive pills? A systematic review. Contraception. 2012 Sep 17. pii: S0010-7824(12)00742-1. doi: 10.1016/j.contraception.2012.08.013. [Epub ahead of print]
   Google Scholar
• Zhang L, Chen J, Wang Y, et al. Pregnancy outcome after levonorgestrel-only emergency contraception failure: a prospective cohort study. Human Reproduction 2009;1:1–7
   Google Scholar
• Cleland K, Raymond E, Trussell J, et al. Ectopic pregnancy and emergency contraceptive pills: a systematic review. Obstet Gynecol 2010;115:1263–6
   PubMed Web of Science ®Google Scholar
• Australian Public Assessment Report for Mifepristone, 2012; http://www.tga.gov.au/pdf/auspar/auspar-mifepristone-121002.pdf; retrieved 21.1.2013
   Google Scholar
• EMA: CHMP assessment report for ellaOne (2009) (http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001027/WC500023673.pdf)
   Google Scholar
• EMA - summary for the public: ellaOne. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/001027/WC500023671.pdf
   Google Scholar
• Gemzell-Danielsson K, Berger C, P G L L. Emergency contraception - mechanisms of action. Contraception. 2012 Oct 29. pii: S0010-7824(12)00750-0. doi: 10.1016/j.contraception.2012.08.021. [Epub ahead of print]
   Google Scholar
• Stratton P, Hartog B, Hajizadeh N, et al. A single mid-follicular dose of CDB-2914, a new antiprogestin, inhibits folliculogenesis and endometrial differentiation in normally cycling women. Hum Reprod 2000;15:1092–9
   PubMed Web of Science ®Google Scholar
• Stratton P, Levens ED, Hartog B, et al. Endometrial effects of a single early luteal dose of the selective progesterone receptor modulator CDB-2914. Fertil Steril 2010;93:2035–41
   PubMed Web of Science ®Google Scholar
• Gemzell-Danielsson K, personal communication, 24.01.2013
   Google Scholar
• Mutter GL, Bergeron C, Deligdisch L, et al. The spectrum of endometrial pathology induced by progesterone receptor modulators. Mod Pathol 2008;21:591–8
   PubMed Web of Science ®Google Scholar
• Rabe T, Ahrendt HJ, Albring C, et al. Ulipristalacetat bei symptomatischem Uterus myomatosus und bei myombedingter Hypermenorrhoe. Gemeinsame Stellungnahme der DGGEF und des BVF Reproduktionsmed. Endokrinol 2012;9:106–126. http://www.kup.at/kup/pdf/10769.pdf
   Google Scholar
• Task Force on Postovulatory Methods of Fertility Regulation. Randomised controlled trial of levonorgestrel versus the Yuzpe regimen of combined oral contraceptives for emergency contraception. Lancet 1998;352:428–33
   PubMed Web of Science ®Google Scholar
• Stefan van der Geest for HRA Pharma, personal communication (30.1.2013)
   Google Scholar